Description
Kalorama Information’s In Vitro Diagnostic (IVD) Trends and Market Update, 2025 provides the latest insights into the dynamic IVD market amid ongoing economic and global uncertainties. Published twice a year—first in April 2025 and again in Q4 2025, following the release of Kalorama’s annual 1,600-page study, The Worldwide Market for In Vitro Diagnostics (IVD), 18th Edition—this report serves both as a standalone resource and a companion to Kalorama’s annual flagship IVD analysis.
In 2024, the IVD market continued to expand, with most segments experiencing growth, despite the decline in COVID-19 testing revenues. AI-driven innovations, regulatory shifts, and changes in global healthcare spending are shaping the competitive landscape, reinforcing the resilience of the IVD sector.
Key growth areas attracting industry attention and that are anticipated to play a significant role in the future of IVD include:
- Point-of-care diabetes testing
- Companion diagnostics technologies
- Immunochemistry
- Mass spectrometry
- Nucleic acid assays
- Gene testing
- HPV molecular diagnostics
This report delivers timely and actionable intelligence, covering:
- Market drivers and major industry trends
- New product developments shaping IVD innovation
- Competitive landscape insights and activities of key players
- Emerging opportunities and strategic growth areas
With a commitment to delivering precise and up-to-date market intelligence, Kalorama Information continues to provide industry stakeholders with critical data and expert analysis to navigate the ever-evolving IVD landscape.
Table of Contents
Chapter 1: Worldwide IVD Market Update – April 2025
IVD Market Demand and Growth
- Figure 1-1: Segment Performance Commentary, Q1-Q4 2024
- Table 1-1: Global In Vitro Diagnostic Sales, by Product Market, 2024 ($ million) [Blood bank molecular – NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology – Core Lab, Histology/cytology, HPV, molecular, Immunoassays – non-isotopic (Immuno – Infectious disease, Other immune, Immuno – Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology – Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
- Figure 1-2: Quarterly IVD Segment Performance, by Segment, Q1 2024 – Q4 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
- Figure 1-3: IVD Segment Performance, Total Market Value, 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
COVID-19 Diagnostic Markets
- Table 1-2: COVID-19 Product Sales, 2024 ($ million) [Immunoassay (Antigen, Serology), Molecular, Rapid]
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market Excluding and with COVID-19, 2024 ($ million)
- Figure 1-4: IVD Market Distribution, by Segment, 2024 (%) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
- Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, 2024 ($ million) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
- Table 1-4: Global In Vitro Diagnostic Market, YoY Growth 2023-2024 (%) [Blood bank molecular – NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology – Core Lab, Histology/cytology, HPV, molecular, Immunoassays – non-isotopic (Immuno – Infectious disease, Other immune, Immuno – Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology – Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
- Figure 1-6: Global In Vitro Diagnostic Market – YoY Growth 2023-2024 (%) [Blood bank molecular – NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology – Core Lab, Histology/cytology, HPV, molecular, Immunoassays – non-isotopic (Immuno – Infectious disease, Other immune, Immuno – Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology – Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
Chapter 2: Product Trends and New Developments
Liquid Biopsy
Mass Spectrometry
Immunoassay
Molecular
Personalized Medicine
POC
Sequencing
Antigen/Antibody
Molecular
Chapter 3: Top IVD Market Participant Results
Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2023-2024 (%) [Abbott Diagnostics, Becton Dickinson, bioMérieux, Danaher, Dexcom, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific]
- Figure 3-2: IVD Sales Changes in Market Distribution, 2021-2024 – Roche and Abbott Battle for #1 Spot (%) [Abbott Diagnostics, Becton Dickinson, bioMérieux, Danaher, Dexcom, Exact Sciences, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen, Others]
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2022-2024 ($ million)
Q4 2024, Q1 2025 M&A Activity
- Table 3-1: Q4 2024, Q1 2025 Merger and Acquisition Activity
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
bioMérieux SA
- Table 3-4: bioMérieux Corporate Summary
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
Dexcom, Inc
- Table 3-6: Dexcom Corporate Summary
Exact Sciences
- Table 3-7: Exact Sciences Corporate Summary
QuidelOrtho Corporation
- Table 3-8: QuidelOrtho Corporate Summary
Roche Diagnostic
- Table 3-9: Roche Diagnostic Corporate Summary
Siemens Healthineers
- Table 3-10: Siemens Healthineers Corporate Summary
Sysmex Corporation
- Table 3-11: Sysmex Corporate Summary
Thermo Fisher Scientific
- Table 3-12: Thermo Fisher Scientific Corporate Summary
Chapter 4: New Opportunities
Staffing Shortages
LDT Update
IVDR Compliance Deadline Approaches
- Table 4-1: IVDR New Risk-based Classification System
Telemedicine
